BioClinica®, Inc. BIOC, a leading global provider of clinical trial
management solutions and JLL Partners, Inc. (“JLL”), a leading private equity
investment firm, announced today that BC Acquisition Corp. (“Purchaser”),
which is a wholly-owned subsidiary of BioCore Holdings, Inc. (“Parent”), each
of which is an affiliate of JLL, has commenced a tender offer for all
outstanding shares of BioClinica at a price of $7.25 per share net to the
seller in cash. The offer is being made pursuant to a definitive merger
agreement pursuant to which Parent will acquire BioClinica. Parent and
Purchaser are affiliates of JLL Partners Fund VI, L.P. (the “Sponsor”), which
is a private equity investment fund managed by JLL.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in